Evaluation of the effect of calcitriol combined with sevelamer carbonate in the treatment of maintenance hemodialysis patients
骨化三醇联合碳酸司维拉姆治疗维持性血液透析患者的效果评价

摘要

目的 探讨骨化三醇联合碳酸司维拉姆治疗维持性血液透析患者的效果评价。方法 选择于2021年1月-2024年12月内收治的行维持性血液透析患者100例，将其按随机分组方法分为对照组（50例，采取碳酸司维拉姆治疗）和观察组（50例，采用骨化三醇联合碳酸司维拉姆治疗），对比两组临床治疗效果。结果 观察组肾功能指标水平均低于对照组（P＜0.05），炎症指标水平低于对照组（P＜0.05），生化指标水平优于对照组（P＜0.05）。两组不良反应发生率比对无显著差异（P＞0.05）。观察组临床治疗有效率高于对照组（P＜0.05）。结论 骨化三醇联合碳酸司维拉姆治疗可有效控制患者炎症反应，改善其肾功能，安全性较高，有较高应用价值。

Abstract

Objective This study explores the efficacy evaluation of calcitriol combined with sevelamer carbonate in the treatment of patients undergoing maintenance hemodialysis.
Methods One hundred patients undergoing maintenance hemodialysis, admitted between January 2021 and December 2024, were selected and randomly divided into a control group (50 cases, treated with sevelamer carbonate) and an observation group (50 cases, treated with calcitriol combined with sevelamer carbonate). The clinical treatment effects of the two groups were compared.
Results The renal function indicators in the observation group were lower than those in the control group (P<0.05), the inflammatory indicators were lower than those in the control group (P<0.05), and the biochemical indicators were superior to those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The clinical treatment efficacy in the observation group was higher than that in the control group (P<0.05).
Conclusion   Calcitriol combined with sevelamer carbonate treatment can effectively control patients' inflammatory responses, improve their renal function, and has high safety and application value.